There is evidence from clinical studies to suggest that IL-17A signaling undermines immune checkpoint inhibitors, contributes to immunotherapy resistance, and promotes the development of adverse autoimmune events in cancer patients (Kang et al., 2021). This evidence concerns the gene IL17A and cancer.